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Abstract
Background: C57BLKS/J (BLKS) mice are susceptible to islet exhaustion in insulin-resistant states
as compared with C57BL6/J (B6) mice, as observed by the presence of the leptin receptor (Lepr)
allele, Leprdb/db. Furthermore, DBA2/J (DBA) mice are also susceptible to β-cell failure and share
25% of their genome with BLKS; thus the DBA genome may contribute to β-cell dysfunction in
BLKS mice.
Results:  Here we show that BLKS mice exhibit elevated insulin secretion, as evidenced by
improved glucose tolerance and increased islet insulin secretion compared with B6 mice, and
describe interstrain transcriptional differences in glucose response. Transcriptional differences
between BLKS and B6 mice were identified by expression profiling of isolated islets from both
strains. Genomic mapping of gene expression differences demonstrated a significant association of
expression differences with DBA loci in BLKS mice (P = 4×10-27).
Conclusion: Two genes, Nicotinamide nucleotide transhydrogenase (Nnt) and Pleiomorphic adenoma
gene like 1 (Plagl1), were 4 and 7.2-fold higher respectively in BLKS islets, and may be major
contributors to increased insulin secretion by BLKS islets. Contrary to reports for B6 mice, BLKS
mice do not harbor a mutant Nnt gene. We detected 16 synonymous polymorphisms and a two-
amino acid deletion in the Plagl1 gene in BLKS mice. Several inflammatory glucose-responsive genes
are expressed at a higher level in BLKS, suggesting an inflammatory component to BLKS islet
dysfunction. This study describes physiological differences between BLKS and B6 mice, and
provides evidence for a causative role of the DBA genome in β-cell dysfunction in BLKS mice.
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Background
Type 2 diabetes mellitus can be considered as a two-stage
disease. First the body becomes resistant to circulating
insulin, and second, when coupled with pancreatic β-cell
dysfunction, overt diabetes precipitates [1]. Insulin resist-
ance alone, without β-cell exhaustion, will not lead to
hyperglycemia. In this case the islet compensates by
increasing insulin production and β-cell populations are
maintained. Differences in β-cell adaptation to increased
insulin demand likely reflect an underlying genetic com-
ponent. Indeed, in B6 mice, but not in genetically dissim-
ilar BTBR mice, insulin resistance induced by the leptin ob
allele is well compensated by islet expansion [2]. The
genetic alteration in BTBR mice which underpins this fail-
ure to adapt to increased insulin requirements was
recently identified and localized to a gene contributing to
islet vascularization [3].
Obese (Leprdb/db) B6 and 129/J mice are insulin resistant
but compensate this potentially pathogenic process by
islet hypertrophy and hyperinsulinemia [4,5]. However,
obese (Leprdb/db) DBA mice not only develop insulin
resistance but also severe diabetes due to β-cell loss. Thus
the DBA background may be considered a diabetogenic
strain exhibiting a predisposition to β-cell failure. DBA
mice copiously secrete insulin (10-fold over basal) in
response to a glucose bolus compared with a modest (3-
fold) increase in B6 mice [6]. This hypersecretion pheno-
type (here after referred to as elevated insulin secretion) is
retained in isolated islets, and confirms a functional dif-
ference between these two strains specific to the islet.
These data suggest that elevated secretion of insulin may
be deleterious to the β cell and results in β-cell exhaustion
in DBA mice.
BLKS mice also exhibit pancreatic islet failure when made
insulin resistant by the ob or db Lepr alleles [5,7,8], as evi-
denced by gross islet atrophy and β-cell loss. This strain is
closely related to B6; however, it harbors a small contribu-
tion from the DBA strain. Genetic analysis of the BLKS
mice has uncovered a contribution of approximately 71%
from B6, 25% from DBA, and 4% from other strains in
BLKS mice [9-11]. Given the clear differences in severity of
diabetes between B6-Leprdb/db  mice and BLKS-Leprdb/db
mice, and the similarity between BLKS and DBA mice, it is
tempting to speculate that islet sensitivity may be con-
ferred by alleles from the DBA genome.
In this report we investigated islet function in non-obese
B6 and BLKS mice. We found that BLKS mice are pro-
foundly more glucose tolerant than B6 and this difference
was associated with elevated secretion of insulin in islets.
We investigated the differences in gene expression in iso-
lated islets between the two strains, in both basal and
stimulated (insulin secretion stimulated) conditions, and
found that 75% of the gene expression differences in the
BLKS islets were contributed from genes within DBA loci.
Further, several genes regulated by glucose in both strains
suggest early inflammatory effects associated with
increased glucose (Txnip,Lnc2,Gad1 Slc7a3 and  Spp1).
Notably, we identified significantly higher expression of
Nnt and Plagl1 (ZAC1) in BLKS islets, two genes previ-
ously associated with islet dysfunction.
Results and discussion
Glucose homeostasis in non-obese BLKS and B6 mice
Although glucose homeostasis has been extensively stud-
ied in BLKS-Lepdb/db mice, few reports have shown clear
differences in non-obese BLKS mice compared with B6
mice. To better understand the differences between both
these strains, we analyzed fasting glucose in young (12
weeks old) and aged (26 weeks old) mice. At 12 weeks of
age, fasting glucose levels between B6 and BLKS mice were
similar (113.3 ± 5.7 mg/dL vs. 100.7 ± 3.6 mg/dL, respec-
tively) as well as at 26 weeks (118.4 ± 4.2 mg/dL vs. 111.0
± 17 mg/dL). Interestingly, B6 mice and BLKS mice have
similar body weights at younger ages but after 16 weeks of
age the B6 mice continue to gain weight whereas BLKS
mice do not (Figure 1A). Also, in 12-week-old-mice insu-
lin levels were the same in the two strains (Figure 1B).
However, at 26 weeks B6 mice had significantly higher
insulin levels (P  = 0.018) than BLKS mice, and could
reflect the difference in body weights. We found no differ-
ences in glucagon levels (data not shown). The difference
in insulin levels in older mice may also represent a differ-
ence in glucose homeostasis. To investigate this further,
glucose tolerance tests (GTTs) were performed at 10 and
23 weeks of age (Figure 1B). At both ages, glucose toler-
ance between B6 and BLKS mice was clearly different.
Although 10-week-old B6 and BLKS mice had similar
basal fasting blood glucose levels, at 30, 60 and 120 min
after an intraperitoneal injection of glucose B6 mice were
less glucose tolerant than the BLKS mice. Similar results
were obtained at 23 weeks of age; however, at this age the
basal fasted blood glucose values for the BLKS mice were
statistically lower than the B6 mice. Both lines of mice
were more glucose intolerant at 23 weeks than at 10 weeks
of age (blood glucose spike at 30 min was increased in
both strains). The glucose intolerance observed in the B6
mice at 23 weeks could be related to the higher body
weight and some degree of peripheral of insulin resist-
ance. On the other hand, the younger B6 and BLKS 10-
week-old mice had similar body weights yet clearly were
dissimilar in glucose tolerance; furthermore, a report by
Goren et al [12] illustrated that 8 to 10-week-old B6 and
BLKS mice are very similar when challenged in an insulin
tolerance test. Taken together, we interpret these data to
reflect a pancreatic difference between these two strains to
account for the differences in glucose tolerance.PathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Islet insulin secretion and pancreatic 
immunohistochemistry
To investigate if the enhanced glucose clearance in BLKS
mice was attributed to increased insulin secretion, glu-
cose-stimulated insulin secretion was measured in iso-
lated islets from both B6 and BLKS mice (Figure 2A). Islets
of BLKS mice secreted significantly more insulin than B6
mice at the higher glucose concentrations tested, provid-
ing further support for an elevated secretion phenotype.
These data have been shown for DBA mice [6,13], but to
date have not been reported for BLKS mice.
To determine if the difference in insulin secretion corre-
lated with differences in β-cell mass, we performed histol-
ogy and immunohistochemistry on pancreatic sections
from both strains. No gross differences in islet number or
appearance were observed in either B6 or BLKS mice as
assessed in multiple mice of each strain. Furthermore, fol-
Glucose homeostasis in B6 and BLKS mice Figure 1
Glucose homeostasis in B6 and BLKS mice. (A) Body weights of B6 and BLKS male mice (n = 13 for each strain) were 
monitored from 10 weeks to 26 weeks of age. (B) Fasting (4 h) plasma insulin was analyzed in 10-week (n = 13) and 23-week (n 
= 8) -old B6 and BLKS male mice. (C) Glucose tolerance was assessed in 10 and 23-week-old B6 and BLKS male mice, following 
an intraperitoneal injection of glucose (2 g/kg). All data represent means and s.e.m. and tested using a two-tailed Student's T-
test assuming unequal variances; * P < 0.05, ** P < 0.01, *** P < 0.001.
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Insulin secretion is higher in BLKS mice than B6 mice Figure 2
Insulin secretion is higher in BLKS mice than B6 mice. (A) Glucose-stimulated insulin secretion was investigated in iso-
lated islets from 12-week-old B6 and BLKS male mice. Following 48 h recovery post-isolation, the islets were stimulated with 
2, 10 or 16.7 mM glucose for 1 h. Insulin release into the media was monitored. (B) Immunohistochemistry was performed in 
pancreatic islets from 26-week-old male mice revealing no gross differences in islet appearance or size. Insulin (oxidized DAB-
brown) and glucagon (Vector Blue product) expressing cells are shown. (C) Pancreatic insulin content was assessed in pancre-
ata excised from 15-week-old male B6 and BLKS mice (n = 3/group). No statistically significant differences were detected. All 
data represent means and s.e.m. and tested using a two-tailed Student's T-test assuming unequal variances; * P < 0.05; n.s. not 
significant.
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lowing staining for insulin and glucagon, a similar com-
position of α and β cells within the islet was found (Figure
2B). Thus the difference in insulin secretion was not asso-
ciated with any qualitative difference in β-cell mass. To
investigate if any quantitative differences in β-cell mass
were present between the two strains, we analyzed pancre-
atic insulin content (Figure 3C). Pancreata from BLKS
mice were found to have a small but non-significant
reduction in pancreatic insulin content compared with B6
mice. This, however, is unlikely to explain the elevated
insulin secretion observed in the BLKS mice.
Islet gene expression differences between glucose 
concentrations
Given that islet dysfunction is a characteristic of BLKS-Lep-
rdb/db mice but not of B6-Leprdb/db mice, and is associated
with heightened insulin secretion in non-obese BLKS
mice, we hypothesized that these physiological outcomes
may be reflected in differences in islet gene expression. We
investigated gene expression in normal (non-diabetic)
mice with the intention of analyzing expression in islets
with similar compositions of α, β, and δ cells. Further-
more, we speculated differences in gene expression may
only become apparent after a period of extended secre-
tion, which would expose genes involved in islet dysfunc-
tion/adaptation. To this end, islets were isolated from 10
B6 and 10 BLKS mice, and cultured for 2 days in 11 mM
glucose (each individual mouse's islets were cultured sep-
arately). After this period, islets from five B6 mice were
cultured in 5 mM glucose and from five B6 mice in 20 mM
glucose for an additional 24 h. BLKS islets were treated
similarly. RNA isolated from each individual mouse's
islets was used to investigate global changes in gene
expression between the strains in low and high-glucose
conditions. We assessed the common differences due to
glucose concentration (Table 1), and differences between
strains (Table 2).
Table 1 shows gene expression fold-change differences
between low and high-glucose conditions in BLKS and B6
mice. We highlight the subset with BLKS glucose response
of at least 2-fold. These transcriptional differences associ-
ated with glucose response in islets suggest an underlying
inflammatory component. Lipocalin 2 (Lcn2) transcrip-
tion increases 2.4-fold in response to higher glucose levels
and is 2.07-fold higher in BLKS islets. This gene is regu-
lated by the cytokine leptin in insulinoma cells [14] and
interestingly BLKS mice also have 40% more of a specific
leptin receptor (Leprotl1) at high glucose levels – 1.44 and
1.09-fold under high and low-glucose conditions, respec-
tively. Lcn2 is also known to be up-regulated in rat models
of type 2 diabetes, and associated with inflammatory
functions [15] including apoptosis. The glucose-respon-
sive gene Glutamate decarboxylase 1 (Gad1), which is an
islet-derived autoantigen in insulin-dependent diabetes
[16], may be a marker for β-cell loss or toxicity and has
been shown to be glucose responsive. We observed a Gad1
decrease in both mouse models, but more so in the BLKS
mice. The gene with the largest change due to glucose in
BLKS mice was S100a9. This gene is expressed in mono-
cytes and pancreatic cell lines, and is essential for pancre-
atic leukocyte infiltration [17,18]. In addition to being an
inflammatory marker S100a9  is associated with islet
autoimmunity [19]. Another glucose-responsive gene,
Slc7a3, is likely an indirect marker for the presence of res-
ident islet inflammatory cells. Slc7a3 is a polar amino acid
transporter, which provides L-arginine that can be used in
nitric oxide (NO) production. NO synthesis and overpro-
duction has been associated with β-cell dysfunction in
diabetic rats [20].
In addition to the inflammation-associated genes we also
observed strong induction by glucose of the gene encod-
ing Thioredoxin interacting protein (Txnip) in both BLKS and
B6 mice. Txnip  has been recently linked with glucose-
induced β-cell loss [21]. Chen et al showed that glucose
incubation up-regulated Txnip and increased apoptosis,
which they speculated may be via the intrinsic mitochon-
drial apoptotic pathway. They also showed that constitu-
tive over-expression is not necessary for apoptosis, but
that the glucose-induced increase is sufficient. Further-
more, Parikh et al have shown that, in humans, Txnip
over-expression reduces basal and insulin-stimulated glu-
cose uptake [22], is elevated by glucose and suppressed by
insulin. We confirm the increase of Txnip expression in
response to glucose, although we do not observe any dif-
ferential response to glucose between B6 and BLKS mice.
On the contrary, BLKS mice have 2-fold lower levels of
Txnip than B6 mice. Thus Txnip is unlikely to underlie the
islet failure in BLKS mice, but more likely to represent the
typical response to glucose.
Islet gene expression differences between B6 and BLKS 
strains
Table 2 shows a list of genes which were more than 2.5-
fold different in BLKS islets compared with B6 islets in
high glucose conditions (column 4, High Gluc.). All
members of this list were significantly different between
strains, regardless of glucose concentration, after control-
ling the false discovery rate at 0.80 [23]. In addition to its
induction by glucose within each strain (Table 1) Spp1
expression is also significantly different between strains
and is 3.5-fold higher in BLKS islets (Table 2). Spp1 or
osteopontin is a multifunctional cytokine and a potential
diagnostic predictor of diabetic end-stage renal disease
[24]. Arafat et al have shown that Spp1 averts cytokine-
mediated  β-cell toxicity through negative regulation of
NO production [25]. As we have shown, both BLKS and
B6 mice up-regulate Slc7a3, a gene associated with NO
production, but BLKS mice always express higher levelsPathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Plagl1 expression and genetic differences in BLKS mice Figure 3
Plagl1 expression and genetic differences in BLKS mice. (A) Quantitative RT-PCR analysis of the Plagl1t RNA in B6 and 
BLKS in isolated islet cultured in high glucose conditions. Data represent means and standard deviations of multiple mice (B6 n 
= 8; BLKS n = 4) and tested using a two-tailed Student's T-test assuming unequal variances; *** P < 0.001. (B) Diagram of the 
polypeptide structure of Plagl1 identifying the functional domains. Numbers refer to the mouse amino-acid positions, and let-
ters refer to amino acids. The genetic differences between B6 and BLKS genes are shown by the stars; the two-amino acid 
deletion in BLKS is shown by the arrow.
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Table 1: Gene expression fold-change differences in islets from low to high glucose in BLKS and B6 mice
Probe Gene Description Interstrain fold difference (BLKS/B6) Glucose response (fold change)
Low Gluc. High Gluc. B6 BLKS
A_51_P402943 S100A9 S100 calcium-binding protein A9 1.21 3.28 1.59 4.31
A_51_P438805 TXNIP thioredoxin-interacting protein -1.72 -2.01 4.16 3.56
A_51_P358765 SPP1 secreted phosphoprotein 1 2.46 3.76 2.12 3.24
A_51_P275016 SLC7A3 solute carrier family 7 member 3 1.49 1.97 2.13 2.82
A_51_P372550 CGREF1 cell growth regulator with EF-hand 
domain 1
1.04 1.65 1.76 2.79
A_51_P510156 LCN2 lipocalin 2 1.98 2.07 2.31 2.41
A_52_P94482 TTYH1 tweety homolog 1 1.73 1.84 2.23 2.37
A_51_P194149 TTR transthyretin -1.31 1.13 1.59 2.37
A_51_P428384 TTYH1 tweety homolog 1 1.58 2.19 1.70 2.36
A_52_P326399 FKBP11 FK506-binding protein 11 1.50 1.48 2.39 2.36
A_51_P130727 FKBP11 FK506-binding protein 11 1.65 1.64 2.34 2.33
A_51_P227275 CSN3 casein kappa 1.43 1.54 2.15 2.31
A_51_P370458 A030006P16RIK RIKEN cDNA 1.01 1.64 1.41 2.29
A_51_P391955 2310032F03RIK RIKEN cDNA 1.10 1.21 2.07 2.27
A_51_P346938 LRG1 leucine-rich alpha-2-glycoprotein 1 1.18 1.17 2.22 2.20
A_52_P187058 NPTX2 neuronal pentraxin II 1.67 2.38 1.51 2.16
A_51_P435911 HSD3B7 hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid 
delta-isomerase 7
1.17 1.69 1.46 2.11
A_51_P162955 SERPINA7 serpin peptidase inhibitor member 7 -1.01 1.21 1.69 2.07
A_52_P547328 TRAM1 translocation-associated membrane 
protein 1
1.09 1.51 1.49 2.06
A_51_P272876 FAM46A family with sequence similarity 46, 
member A
1.59 1.72 1.88 2.03
A_52_P144310 GAD1 glutamate decarboxylase 1 1.02 -1.23 -1.63 -2.04
A_51_P199352 2310015B20RIK RIKEN cDNA -1.25 -1.71 -1.62 -2.21
Genes are sorted for the subset with BLKS glucose response (fold change) >2 (p < 0.001, Benjamini-Hochberg FDR 0.8).PathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Table 2: Gene expression fold-change differences in islets from BLKS mice compared with those from B6 mice
Interstrain fold difference (BLKS/B6)
Probe Gene Description Low Gluc. High Gluc. Chromosome Mb Genetic Origin
A_51_P417251 6330403K07RIK RIKEN cDNA 4.32 17.43 11 71.1 DBA
A_52_P532456 PLAGL1 pleiomorphic adenoma gene-
like 1
2.93 7.15 10 12.8 DBA
A_51_P113395 NNT nicotinamide nucleotide 
transhydrogenase
1.94 4.22 13 116.6 DBA
A_52_P395228 NNT nicotinamide nucleotide 
transhydrogenase
2.01 4.07 13 116.6 DBA
A_51_P113399 NNT nicotinamide nucleotide 
transhydrogenase
1.79 3.85 13 116.6 DBA
A_51_P422030 FLJ22709 hypothetical protein 1.99 3.82 8 69.8 DBA
A_51_P358765 SPP1 secreted phosphoprotein 1 2.46 3.76 5 103.6 B6
A_51_P253984 PCP4 Purkinje cell protein 4 1.93 3.52 16 96.9 DBA
A_51_P402943 S100A9 S100 calcium-binding protein 
A9
1.21 3.28 3 90.8 DBA
A_52_P542860 BTBD9 BTB domain-containing 9 1.99 3.27 17 28.7 DBA
A_51_P440682 CAP1 CAP, adenylate cyclase-
associated protein 1
1.82 3.17 4 122.3 DBA
A_52_P3029 AGPAT4 1-acylglycerol-3-phosphate O-
acyltransferase 4
1.42 2.92 17 10.9 DBA
A_51_P323620 THYN1 thymocyte nuclear protein 1 1.74 2.91 9 26.9 other
A_51_P346165 AGPAT4 1-acylglycerol-3-phosphate O-
acyltransferase 4
1.42 2.89 17 10.9 DBA
A_51_P118417 SCPEP1 serine carboxypeptidase 1 1.70 2.87 11 89.0 DBA
A_51_P454873 NPY neuropeptide Y 1.97 2.72 6 49.8 B6
A_51_P491017 GNPTG N-acetylglucosamine-1-
phosphate transferase, gamma 
subunit
1.82 2.71 17 23.4 DBA
A_52_P748882 ENO2 enolase 2 1.62 2.58 6 124.8 DBA
A_51_P167535 FABP3 fatty acid-binding protein 3 1.88 2.53 4 129.8 DBA?
A_51_P130028 ENO2 enolase 2 1.63 2.53 6 124.8 DBA
A_51_P101545 HGFAC HGF activator -1.92 -2.54 5 34.1 DBA
A_51_P337269 ALDOB aldolase B, fructose-
bisphosphate
-1.17 -2.66 4 49.6 B6PathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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(1.49 to 1.97-fold). Thus, the excess capacity for NO pro-
duction in BLKS mice might counter the protective up-reg-
ulation of Spp1. Other genes such as S100a9, Aldob, and
Slc5a10 demonstrate a stronger glucose response in only
one of the mouse strains. S100a9, a diabetes-associated
pro-inflammatory molecule [26], had a much larger
increase due to increasing glucose in BLKS mice (4.3-fold)
vs.  B6 mice (1.6-fold). Aldob, encoding a glycolytic
enzyme that is decreased in human diabetic islets [27],
and  Slc5a10, a sodium/glucose co-transporter, had
stronger induction due to increasing glucose in B6 mice
(1.5 and 3.5-fold respectively) vs. BLKS mice (1.1 and 1.6-
fold respectively).
From Table 2, 32 genes were more than 2.5-fold different
in expression levels in BLKS islets compared with B6 islets;
16 genes were expressed at higher levels and 16 genes
expressed at lower levels. Thirty of these genes displayed
fold differences with magnitudes between 2.5 and 7.15.
However, two genes had notable differences above this
range.
The first, an uncharacterized transcript (6330403K07RIK),
was 17.4-fold higher in BLKS islets. At this time, this
gene's product has no assigned function and has no
known homology to any protein. Interestingly, two pro-
tein sequences were identified from the NCBI gene data-
base corresponding to 6330403K07RIK which had been
translated from DBA genomic sequence and B6 mRNA
sequence and were found to be different. The protein
sequence from DBA mice (AAR87485) was different at
four residues compared with the B6 sequence
(BAB31072) over the 121 residues.
The second gene with profound differential expression
was H2-Q1, with a 29.3-fold lower level in the islets from
BLKS mice. H2-Q1 localizes to the H2 locus in mice on
chromosome 17. B6 mice are known to be isogenic for the
H2b haplotype and BLKS mice are a recombinant con-
genic strain carrying the H2d haplotype [28]. The differ-
ence in H2-Q1 expression likely represents a difference
conferred by the two haplotypes, and the H2-Q1 gene is
possibly not expressed in mice with the H2d haplotype.
A_51_P215627 PLAC9 placenta-specific 9 -1.89 -2.67 14 23.6 DBA
A_52_P644774 ZZEF1 zinc finger, ZZ-type with EF-
hand domain 1
-1.92 -2.73 11 73.0 DBA
A_51_P517075 SERPINF1 serpin peptidase inhibitor, 
clade F member 1
-1.50 -2.78 11 75.5 DBA
A_52_P213889 TMC7 transmembrane channel-like 7 -1.87 -2.83 7 114.5 DBA
A_52_P613498 4833420G17RIK RIKEN cDNA -2.04 -3.01 13 116.7 DBA
A_51_P376656 SYNPR synaptoporin -2.13 -3.08 14 11.4 DBA
A_52_P50496 HLA-A major histocompatibility 
complex, class I, A
-2.23 -3.16 17 32.1 DBA
A_51_P509961 SLC5A10 solute carrier family 5 
member 10
-1.21 -3.24 11 61.8 DBA
A_51_P246677 REC8L1 REC8-like 1 -2.28 -3.61 14 50.5 DBA
A_51_P392518 THUMPD1 THUMP domain-containing 1 -2.83 -4.30 7 115.6 DBA
A_51_P146560 MSLN mesothelin -2.31 -4.36 17 23.9 DBA
A_52_P137500 AK046255 Unknown cDNA -2.70 -5.06 X 131.8 DBA
A_51_P443443 5830417I10RIK RIKEN cDNA -2.75 -5.46 3 89.0 DBA
A_52_P231729 H2-Q1 major histocompatibility 
complex Q1b
-8.74 -29.31 17 33.4 DBA
Shown is the subset with fold change >2.5 under high glucose conditions (p < 0.001, Benjamini-Hochberg FDR 0.8). Genes are sorted by the 
interstrain fold difference in high glucose conditions.
Table 2: Gene expression fold-change differences in islets from BLKS mice compared with those from B6 mice (Continued)PathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Furthermore, another gene from the H2 locus was identi-
fied in Table 2 (H2-K1), and suggests that the influence of
H2 haplotype can manifest in multiple gene expression
differences.
In further studies, we focused on the two genes Plagl1 and
Nnt, which have previously been implicated in islet dys-
function in both humans and mice.
Transcriptional differences in Plagl1 and Nnt
The second-most highly expressed gene in BLKS islets
compared with B6 islets was Plagl1  (7.2-fold higher
expression; Table 2). The expression state and magnitude
was confirmed by qRT-PCR under the same conditions of
high glucose in a separate experiment (Figure 3A). Plagl1
has been previously implicated in human transient neo-
natal diabetes mellitus (TNDM) [29], and can result from
paternal uniparental disomy of chromosome 6, or pater-
nal duplication of 6q24 (the TNDM locus). These genetic
aberrations suggest the disease results from over-expres-
sion of an imprinted gene [29]. If BLKS islets are indeed
predisposed to failure (when confronted with insulin
resistance), then over-expression of Plagl1 would be con-
sistent with the expression observed in human TNDM.
Similarly, mice which over-express the human TNDM
locus (including Plagl1) exhibit impaired glucose home-
ostasis [30]. Several functions for Plagl1  have been
reported [31]. Interestingly, evidence that Plagl1 can regu-
late apoptosis may be relevant to the β-cell dysfunction in
these mice. In BLKS mice, the Plagl1 gene is within a locus
predicted to be inherited from the DBA parental strain. To
investigate the underlying cause for the difference in
Plagl1  expression we sequenced the four exons of the
gene. Contrary to the published DNA sequence of Plagl1
in B6 mice, BLKS mice have 16 synonymous polymor-
phisms and a two-amino acid deletion (623Glu-624Pro;
Figure 3B). These polymorphisms are contained within
the third exon of the gene. The 16 synonymous polymor-
phisms may not affect the function of the protein, but
could perhaps contribute to the higher expression of the
Plagl1 transcript by affecting RNA stability. Additionally
the 6 bp deletion could alter the RNA stability or possibly
change the function of the protein product. The 623Glu-
624Pro deletion in BLKS mice lies at the end of a repetitive
Pro-Glu-Gln repeat region not found in the human para-
log. Despite this structural difference within the Plagl1
gene of human and mice, functional differences have not
been observed [31]. Thus it is uncertain whether the dele-
tion of the 623Glu-624Pro is functionally relevant to the
β-cell phenotype in BLKS mice.
We observed three different probes for Nnt  that all
showed a clear difference in expression (Table 2). On
average, the Nnt was expressed at 4-fold higher levels in
BLKS islets in high-glucose conditions. It was observed
that the differences in Nnt expression were present in islets
cultured in low-glucose conditions (Table 2, column 4);
however, this was greater in islets following a stimulated
pretreatment. B6 mice were recently shown to be glucose
intolerant, as a result of impaired insulin secretion, and
this was linked to mutation of the Nnt gene [32]. In this
study, a quantitative trait locus (QTL) analysis in B6 and
C3H/HeH mice revealed that expression of Nnt was 5-fold
lower in B6 islets, and is similar with the 4-fold level we
observed compared with BLKS islets. Nnt is a nuclear-
encoded mitochondrial protein involved in detoxification
of reactive oxygen species [33], which is crucial for their
removal and to reduce their deleterious effect on mito-
chondrial ATP production. Intact Nnt will likely lead to
higher ATP levels and thus enhanced insulin secretion in
the β cell. To confirm the role of Nnt in insulin secretion,
B6 mice were rescued with an Nnt  transgene which
improved the insulin secretion [34]. Furthermore,in vitro
analyses using insulin-secreting Min6 cells and isolated
islets with reduced Nnt  function demonstrated dimin-
ished insulin secretion associated with lower ATP levels
[35]. An intact Nnt  gene might be expected to lead to
higher ATP levels in BLKS β cells and thus increased insu-
lin secretion.
To investigate the origin of the Nnt gene in BLKS mice, we
first investigated its genomic location at 116.1 Mb on
chromosome 13 and found that this locus was predicted
to be derived from the DBA parental genome [9], suggest-
ing that the gene in BLKS mice was intact. Next, we
sequenced the first coding exon, previously reported to
contain a point mutation in B6 mice [32]. In DBA mice,
codon 35 reads ATG, resulting in methionine, whereas in
B6 mice this codon is ACG, resulting in threonine. We
found that the DBA strain contributed this exon of the Nnt
gene in BLKS mice due to the presence of the ATG at
codon 35 (Figure 4A). B6 mice also have a deletion of
exons 8 to 11 in this gene [32]. To confirm that the BLKS
mice did not carry this multi-exon deletion we performed
RT-PCR on islet RNA with primers spanning the deletion
(Figure 4B). Corresponding to the intact gene from DBA
mice, a 1497 bp amplicon was generated from the DNA of
BLKS mice, whereas in B6 mice a smaller 743 bp fragment
was observed, as expected, due the deletion. We also
observed two smaller fragments of 402 and 598 bp in B6,
and inspection of the gene sequence suggests that these
fragments are likely a result of the mis-splicing of exon 7
to exons 13 and 14. Altogether, these data show that Nnt
is contributed by the DBA strain in BLKS and is intact, in
contrast to the disrupted B6 gene. Thus, the higher islet
expression of Nnt in BLKS mice relative to the B6 mice is
most likely due to the lack of mutation in the DBA-
derived allele, and may lead to higher ATP levels and
higher insulin secretion, accounting for the enhanced glu-
cose tolerance. Recently a study was published identifyingPathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Nicotinamide nucleotide transhydrogenase is derived from the DBA strain in BLKS mice Figure 4
Nicotinamide nucleotide transhydrogenase is derived from the DBA strain in BLKS mice. (A) Sequencing of exon 
1 of the Nnt gene in BLKS and B6 mice confirms the DBA origin of the gene in the BLKS genome. B6 mice possess the codon 
for threonine (Thr) at residue 35, whereas the BLKS mice have the codon for methionine (Met). (B) RT-PCR analysis of the 
Nnt RNA in B6 and BLKS. A smaller RT-PCR fragment is amplified from B6 RNA (743 bp) than BLKS RNA (1798 bp), confirm-
ing the deletion of exons 8 to 11 previously described in B6 mice [32]. The two smaller bands (bracket) in B6 mice are likely 
mis-splicing artifacts from downstream exons which are flanked by the PCR primers. M – marker.
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a strong QTL on chromosome 13 governing insulin hyper-
secretion in a B6 × DBA cross [36]. Nnt was identified as
the likely candidate gene and higher gene expression and
intact gene structure was observed in islets. These data
support our results and confirm the fact that Nnt gene is
inherited from the DBA genome in BLKS mice.
The observations of altered expression of Plagl1 and Nnt
between these two strains could account for the pheno-
typic differences observed in insulin-resistant states, such
as enforced by deficiency of leptin or its receptor. Their
individual prior association with human and/or mouse
diabetes suggest these genes are functionally relevant to
the proper action or survival of the β cell. The expression
differences of these two genes alone may possibly be suf-
ficient to elicit a physiological effect through their interac-
tion. Indeed, the elevated secretion of insulin expected in
β cells with intact Nnt function may precipitate an apop-
totic event in a pro-apoptotic, Plagl1-enriched cell.
Expression differences are mainly contributed by the DBA 
loci
We hypothesized that the DBA genome contributes to the
islet dysfunction. The locations of the DBA blocks in the
BLKS genome have been mapped by other groups [9-11].
We noticed that Plagl1 and Nnt were located in DBA loci
of the BLKS genome, and investigated the genetic origin of
the other genes in Table 2. We found that 28 out of these
32 genes were derived from DBA loci (Table 2, last three
columns), based on the genetic mapping of Davis et al [9].
We extended these observations of genomic location and
expression fold change to the entire genome. Using the
published mapping data [9] we identified the B6, DBA,
and Other loci. Other loci were informative regions, but
not classifiable as either B6 or DBA. Within these loci we
mapped all the probes used in the profiling experiment
and combined these data (Additional file 1, supplemental
figure). All of the probes were segregated into genome
sets, based on location of parental genomes (as described
for Additional file 1, supplemental figure). Not all probes
could be mapped and were labeled as unmapped, due to
the inability to assign probes in intervals between markers
derived from different strains. Figure 5 shows the fold
changes of the probe sets from the B6, DBA and Other
genomes. Microarray probes appear to be uniformly dis-
tributed across the mouse genome, and among the haplo-
type blocks. As the threshold increases, the contribution
of the B6 genome declines, and no differences above a
threshold of 3.5 were detected (Figure 5). In contrast to
the B6 contribution, the contribution of the DBA genome
increases as the fold change cut-off increases. At a 2-fold
change or greater cut-off, we observed that 75% of the
probes were DBA in origin, representing 10 times as many
B6 probes. Furthermore, these data show a contribution
of the Other genome within the range of 2 to 4-fold; up to
23% of the probes with a fold change greater than or equal
to four are from genes located in the Other genome.
We used the Kruskal-Wallis test to determine if there was
a statistical difference in global gene expression fold-
change distributions between probes from the different
genomes. At the level of the whole genome, we found
there was very high statistical significance for fold-change
differences between DBA, B6 and Other (χ2 = 126.52, P <
4× 10-27, for probes with significant [P < 1× 10-6] fold
changes). We also investigated each chromosome individ-
ually using the same test, and found that many chromo-
somes showed significant differences in fold change
between block types (Additional file 1, supplemental
table). Chromosomes 6, 7, 8, 13 and 17 were all signifi-
cant for fold-change distribution differences between the
genomes. These data indicate an association of the DBA
loci with the gene expression differences in BLKS mouse
islets. In a QTL screen to identify loci which influence
metabolic phenotypes between B6 and BLKS mice, Mu
and colleagues [37] identified two suggestive LOD scores
for plasma glucose on chromosomes 8 and 17, both iden-
tified in our study to harbor significant gene expression
differences. Additionally, the recent report by Aston-
Mourney and co-workers [36] identified suggestive LOD
scores for insulin secretion on chromosomes 5, 6 and 7,
of which two were identified in our study.
Conclusion
We have analyzed the physiological differences between
B6 and BLKS mice with attention to their glucose home-
ostasis/islet phenotype. We have shown several transcrip-
tional differences linked to diabetes and inflammatory
mechanisms leading to islet damage. Glucose stimulation
appears to elicit inflammatory responses, and particularly
increases in the genes Lcn2,  Spp1,  S100a9, and Slc7a3.
These changes are seen in both strains, but expression is
always higher in BLKS mice. Altogether this suggests that
islet dysfunction in BLKS has a strong inflammatory com-
ponent. The largest islet gene expression differences were
in Plagl1 and Nnt, two genes implicated in β-cell biology.
We identified genetic differences in these genes between
the two strains. The interaction of these two genes may
account for the β-cell dysfunction commonly observed in
BLKS mice. Lastly, we undertook a genomic approach to
translate islet expression data, and revealed a significant
and primary contribution from the DBA genome. These
data demonstrate the utility of combining genomic,
genetic, and physiological data to aid in the delineation of
multi-factorial phenotypes.PathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Methods
Animal studies
All mice were maintained in accordance with the Institu-
tional Animal Use and Care Committee of Amgen Inc. B6
and BLKS male mice were obtained at 6 weeks of age from
The Jackson Laboratory (Bar Harbor, ME). Mice received
food and water ad libitum and were maintained on a 12:12
h light-dark cycle (lights on at 6:30 am) and housed one
per cage. Fasting (4 h) blood samples (150 μl) were col-
lected from the retro-orbital sinus of non-anesthetized
mice into EDTA plasma tubes and blood glucose was
measured using a OneTouch Profile glucometer (LifeScan,
Milpitas, CA). For GTT, mice were fasted from 9:00 pm to
9:00 am. Blood glucose was measured at 9:00 am, and an
intraperitoneal glucose bolus (2 g/kg body weight) was
administered to conscious, unrestrained mice. During the
GTT, blood glucose was measured at 30, 60 and 120 min.
Plasma insulin levels were analyzed using the LINCOplex
mouse endocrine immunoassay panel following the man-
ufacturer's instructions (Millipore, St. Charles, MO).
Gene expression differences in BLKS islets demonstrate a major contribution by DBA located probes Figure 5
Gene expression differences in BLKS islets demonstrate a major contribution by DBA located probes. Gene 
expression fold-change differences for all probes in the experiment were assigned to either B6, DBA or Other genomes based 
on chromosomal location. The percentage of probes greater than the fold change threshold (t) are plotted against t for each 
set of genomically assigned probes. The contributions at a threshold of 1 reflect the baseline genomic contribution of these 
probes. As the fold change threshold increases, the B6 differences sharply decline, whereas the DBA probes increase their con-
tribution. Above a fold change of 4.5, all of the expression differences are accounted for by DBA assigned probes.
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Pancreatic islet isolation
Pancreatic islets were isolated from 12-week-old mice.
After clamping the common bile duct as it joins the intes-
tine, the pancreas was inflated with 5 ml of collagenase
type XI (0.6 mg/ml; Sigma-Aldrich, St. Louis, MO) diluted
in Hanks balanced salt solution (HBSS; Sigma-Aldrich).
The distended pancreas was removed and incubated at
37°C for 10 min, and the islets were dispersed by gentle
shaking. Enzymatic digestion was stopped by the addition
of 45 ml of cold HBSS containing 10%FBS. Two rounds of
centrifugation (300× g for 2 min) and washes with fresh
HBSS/FBS were carried out, and the islets were resus-
pended in 10 ml of HBSS/FBS buffer. The slurry was lay-
ered on top of a prepared histopaque gradient (comprised
of a 10 ml lower layer of Histopaque 1.119, and 10 ml
upper layer of Histopaque 1.077; Sigma-Aldrich). Follow-
ing centrifugation of the gradient at 1000× g for 30 min,
the islets were collected from the top of the 1.077 inter-
face, pipetted onto a 70 μm cell strainer, and washed with
HBSS/FBS buffer. Finally, the islets were rinsed into a Petri
dish, isolated from any contaminating exocrine material
visually using a dissecting microscope, and cultured in
RPMI-1640 media (Cellgro, University of Miami, FL),
supplemented with 10%FBS and 100 U/ml of penicillin,
and 100 μg/ml of streptomycin at 37°C in 5% CO2. Prior
to all experiments, islets were cultured for 48 h in RPMI-
1640 media containing 11 mM glucose, and reselected for
use based on morphology as assessed with a dissection
microscope.
Glucose-stimulated insulin secretion assay
Twenty-four hours prior to the secretion assay, islets were
picked into 24-well inserts (Multiwell Insert System, 8.0
μm pore size; BD Biosciences, San Jose, CA) in groups of
10 similarly sized islets and cultured in 1 ml/well RPMI-
1640. For the insulin secretion assay, Krebs-Ringer Bicar-
bonate (KRBH) Buffer was prepared (129 mM NaCl, 4.8
mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4.7H2O, 10 mM
HEPES, 2.5 mM CaCl2.2H2O and 4.8 mM NaHCO3) and
oxygenated for 15 min with 95%O2/5%CO2. Bovine
serum albumin (fatty acid-free, Cat. No. A6003; Sigma-
Aldrich) at a final concentration of 0.625% was added to
the buffer, then the buffer was warmed to 37°C and pH
adjusted to 7.4 with 5 M NaOH. The islets were starved for
one hour at 37°C in KRBH + 1 mM glucose (Cat. No. 99-
787-CI, Cellgro) by transferring the 24-well insert from
the RPMI-1640 culture media to a new 24-well plate con-
taining 1 ml/well KRBH + BSA and 1 mM glucose. The
islets were transferred to the experimental plates contain-
ing 1 ml/well of KRBH + BSA and 1 mM, 10 mM and 16.7
mM glucose. Following a one-hour incubation at 37°C,
the insert containing the islets was removed and the buffer
plate frozen at -80°C. The insulin ELISA was carried out
using the Ultra Sensitive Mouse Insulin ELISA kit (Cat.
No. 90080; Crystal Chem Inc. Downers Grove, IL). Five
microliters of each buffer sample was run in duplicate per
assay protocol.
DNA and RT-PCR analysis
DNA was isolated from tail tissue and used for PCR and
direct sequencing analysis of the Nnt gene. RT-PCR using
the One-Step System (Invitrogen, Carlsbad, CA) and islet
RNA was performed using the oligonucleotides, Nnt for-
ward-TACAAGAGCTGCCGCTTTGGA, and Nnt reverse-
AGACCCACTAAAGGTGACTCCG; the product was used
for direct DNA sequencing.
qRT-PCR
RNA isolation kits from QIAGEN (micro-RNAeasy kit;
Valencia, CA) were used to prepare RNA from purified
islets with a final eluate of 15 μl per mouse. RNA was
quantified using Agilent's 2100 Bioanalyzer (Santa Clara,
CA). Real time PCR was performed using 0.2 μM of Plagl1
primer and probe (forward-TCAAGTGCTCGAAGGCT-
GAGT, reverse-TGTGTGGCCATGTGTCTCATC, probe-
FAM-TGGCAAAGCCTTCGTCTCCAAGTATAAGC-BHQ).
Primers were derived from different exons to avoid ampli-
fication of any residual genomic DNA. The RT-PCR reac-
tions were done using QIAGEN's Quantitect Multiplex
RT-PCR kit. The total reaction volume was 20 μl per well
and 20 ng RNA per reaction. Eight replicates of islets iso-
lated from B6 and four replicates of BLKS were run with
cyclophilin used as the housekeeping gene. Amplification
and quantification of PCR products was performed on an
ABI Prism 7900 (Applied Biosystems, Foster City, CA).
Data were exported into Excel and analyzed using the
delta CT method.
Islet histology
Pancreata were removed and fixed in buffered zinc forma-
lin and embedded in paraffin. Pancreas sections (5 μm)
were deparaffinzed, hydrated and blocked for non-spe-
cific reactivity with CAS block (Zymed Lab., San Francisco,
CA). Sections were incubated with guinea pig anti-swine
insulin (A562; DAKO, Carpinteria, CA) at 1:3000 for 45
min at room temperature. Insulin was detected by bioti-
nylated goat anti-guinea pig (BA-7000; Vector Laborato-
ries Inc., Burlingame CA) at 1:100. Slides were quenched
with 3% H2O2  and followed with avidin-biotin HRP
Complex (Vector Lab., Burlingame CA). Reaction sites
were visualized with DAB (DAKO). Next, slides were
rinsed with PBS thoroughly and incubated with rabbit
anti-human glucagon (A565; DAKO) at 1:800 for 1 h at
room temperature. Glucagon was detected by a bioti-
nylated goat anti-rabbit secondary (BA-1000; Vector Lab.)
at 1:200 and followed with avidin-biotin alkaline phos-
phatase complex. Reaction sites were visualized with alka-
line phosphatase substrate (Vector Lab.).PathoGenetics 2009, 2:1 http://www.pathogeneticsjournal.com/content/2/1/1
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Experimental design for islet expression profiling
We investigated gene expression differences in islets from
B6 and BLKS mice and between pretreatments in the pres-
ence of low (5 mM) and high glucose (20 mM) in the cul-
ture media (to simulate basal and stimulated conditions
respectively). To provide >85% confidence that each fold
change >1.5 was true, we used n = 5 per group. To elimi-
nate differences in gene expression contributed by varia-
tion across mice within a group, we did not pool islets
from different animals but kept them separate. Islets were
then cultured separately for 24 h in RPMI-1640 media
containing either 5 mM or 20 mM glucose. At the end of
the culture pretreatment, the islets were picked from the
culture vessel, rinsed briefly in HBSS/FBS buffer and
homogenized in RLT buffer. RNA was prepared using the
micro-RNAeasy kit (QIAGEN). On average, 580 ng of
total RNA was recovered from the isolated islets from each
individual mouse.
Pancreatic insulin content
Pancreata were excised and frozen in liquid nitrogen and
stored at -80°C. Protein content was determined using the
BCA Protein Assay Kit (Thermo Scientific Rockford, IL)
following homogenization of the pancreata for 2 min at
25 Hz in 1 ml of 0.18 M HCl and 70% ETOH in a Tissue-
Lyser (Qiagen Gmbh, Germany). The tissue lysate was
clarified for 10 min at 4000 rpm and the supernatant was
transferred to a fresh microcentrifuge tube. For the protein
assay, the supernatant was 10× diluted in PBS. The insulin
content assay was performed using Ultra Sensitive Mouse
Insulin ELISA kit (Crystal Chem). The tissue lysate was
diluted 1000× and 6000× with sample diluent supplied
with the kit before running the assay. All samples for both
assays were run in duplicate.
Expression profiling
Total RNA was profiled following the Agilent Two-Color
Microarray-Based Gene Expression Analysis Protocol
v4.0.2. Briefly, 200 ng of total RNA from each sample was
separately amplified and labeled with Cy3- and Cy5-
labeled CTP (Perkin Elmer; Wellesley, MA) using the Agi-
lent low-input linear amplification kit. Labeled cRNA was
purified using the Qiagen RNeasy Mini kit protocol for
liquid samples (QIAGEN). Purified cRNA was quantified
using the Nanodrop Fluorospectrometer ND-3000
(Wilmington, DE). Similar amounts of Cy3- and Cy5-
labeled cRNA were combined and fragmented for 30 min
at 60°C. The products were hybridized to Agilent Mouse
Whole Genome Microarrays, and the resulting array data
were extracted using Agilent Feature Extraction Software
v8.1.
Bioinformatic analysis
Raw data for each array were analyzed with Matlab soft-
ware (The Mathworks Inc. Natick, MA). Data were not
analyzed as dye ratios, but as dye-normalized relative flu-
orescence units (RFUs). Dye normalization was accom-
plished by pairing Cy3 and Cy5 values, and determining
the effect of dye on RFU magnitude by including dye as a
factor in an ANOVA analysis of the binary logarithm-
transformed probe intensities, including all two-factor
interactions. The other factors in the ANOVA were strain
and glucose pretreatment. Found to be significant, the
effect of reporter dye was subtracted in a least-squares
manner. Ultimately, technical and then biological repli-
cates were averaged prior to fold-change calculations. Raw
and normalized data discussed in this publication have
been deposited in National Center for Biotechnology
Information's Gene Expression Omnibus (GEO, http://
www.ncbi.nlm.nih.gov/geo/) and are accessible through
GEO Series accession number GSE11257.
Genotyping data from Davis et al [9] were used to divide
the genome into DBA and B6 regions. Each region is bor-
dered by two markers for the same strain with no interven-
ing markers of any other strain. Regions with informative
SNPs, not attributable to DBA or B6 were labeled Other.
Each microarray probe was mapped to a region by deter-
mining if its target gene overlapped with any identified
region. Probes not mapped to one of the three regions
above were labeled as Unmapped. Fold-change distribu-
tions of the four classes of probe were compared using the
Kruskal-Wallis test, a nonparametric ANOVA testing the
hypothesis that groups have the same median fold-change
rank. Fold changes were calculated between BLKS and B6
mice under high-glucose conditions, and those with a
strain effect P value of < 1 E-6 were used in the test. This
test, for differences between regions, was executed for the
entire genome and for each chromosome individually.
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